Cost-effectiveness of difelikefalin for the treatment of moderate to severe chronic kidney disease-associated pruritus (CKD-aP) in adult patients receiving in-centre haemodialysis

Previous PostEstimates on waste of breast cancer related chemotherapy drugs in the NHS (England)
Next PostA comparison of Health Technology Appraisal (HTA) timelines and requirements for orphan technologies in 10 European countries